Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally advanced or metastatic clear cell...
The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with metastatic prostate cancer and loss of...
The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory...
Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of grade 3 or higher...
Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade...
All three tested Niktimvo dosing regimens led to statistically significant overall response rates in patients who have undergone allogenic hematopoietic...
Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of...
83% of participants on an oral Sirturo-containing regimen achieved a favorable outcome compared to 71% of patients on the control...
The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination...
In patients with hormone-receptor (HR)-positive metastatic breast cancer and low or ultra-low levels of HER2 expression, Enhertu led to a...
